Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 1 month from now) | |
US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 3 months from now) | |
US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(1 year, 5 months from now) | |
US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(1 year, 6 months from now) | |
US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(2 years from now) | |
US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(2 years from now) | |
US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(3 years from now) | |
US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(3 years from now) | |
US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(3 years from now) | |
US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(5 years from now) | |
US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(5 years from now) | |
US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(5 years from now) | |
US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(6 years from now) | |
US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(7 years from now) | |
US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(8 years from now) | |
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(10 years from now) | |
US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(11 years from now) |
Evzio (Autoinjector) is owned by Kaleo Inc.
Evzio (Autoinjector) contains Naloxone Hydrochloride.
Evzio (Autoinjector) has a total of 33 drug patents out of which 0 drug patents have expired.
Evzio (Autoinjector) was authorised for market use on 19 October, 2016.
Evzio (Autoinjector) is available in solution;intramuscular, subcutaneous dosage forms.
Evzio (Autoinjector) can be used as method for confirming dose delivery, use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle, use of an auto injector to administer naloxone hcl, use of a delivery device to deliver a dose of naloxone, use of a delivery device to administer a dose of naloxone.
The generics of Evzio (Autoinjector) are possible to be released after 20 March, 2035.
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Method for confirming dose delivery; Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone; Use of an auto injector to administer naloxone h...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic